Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CRG-150
- Development stage
- Phase 2
- Lead developer
- CoRegen
- Modality
- Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
CRG-150 is an autologous, gene-edited T regulatory (Treg) cell therapy being developed by CoRegen, Inc. for the treatment of advanced solid tumors. The therapy involves the genetic modification of a patient's own Treg cells to enhance their therapeutic potential or target specificity within the tumor microenvironment. CRG-150 is currently being evaluated in a Phase 1/2a clinical trial (NCT06483100) to assess its safety, tolerability, and preliminary efficacy in patients with relapsed or refractory HR+/HER2- breast cancer, triple-negative breast cancer (TNBC), and prostate cancer. This approach represents a novel application of Treg cells, which are traditionally associated with immune suppression, to modulate the immune response against malignancies.
02
Targets
CCR4 (C-C Motif Chemokine Receptor 4)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)LAG3 (Lymphocyte activation Gene-3 protein)PDCD1 (Programmed cell death protein 1 receptor)CD274 (Programmed cell death protein 1 ligand 1)NCOA3 (Nuclear receptor coactivator 3)
Beyond the preview
Go deeper on CRG-150.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CRG-150.